Clopidogrel News and Research

RSS

Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Anticoagulation lowers subclinical leaflet thrombosis after TAVI procedure

After transcatheter aortic valve implantation (TAVI), anticoagulation reduced imaging signs of clot formation on the new valve compared with antiplatelet therapy, without compromising safety. This was the main finding of the ACASA-TAVI trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in JAMA.

31 Aug 2026

Trial shows antiplatelet therapy needs personalization after stent implantation

Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at high ischemic risk who had undergone stent implantation 12 months earlier.

29 Aug 2026

Potent antiplatelet therapy increases bleeding risk after heart attack in AF patients

Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with atrial fibrillation after a heart attack.

29 Aug 2026

Potassium-competitive acid blockers match proton pump inhibitors for preventing bleeding after PCI

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) increases the risk of upper gastrointestinal bleeding (UGIB).

20 Aug 2026

New protein discovery could lead to safer antithrombotic therapies

Antiplatelet drugs are one of the main tools used to prevent thrombus formation in people who have had a heart attack or stroke or who have cardiovascular diseases with a high thrombotic risk.

17 Jun 2026

Oral bacteria can reveal your true biological age and health risks

A simple oral rinse may predict biological age, linking oral microbiome changes to aging, frailty, and chronic disease risk in a noninvasive manner.

21 Apr 2026

Redefining cardiovascular care for women

Cardiovascular disease (CVD) remains the leading cause of death for women across the globe, yet significant progress has been made in prevention, diagnosis and management thanks to more sex-specific research, as noted in a special Go Red for Women issue of Circulation, the American Heart Association's flagship, peer-reviewed scientific journal, published today.

17 Feb 2026

Investigational anti-clotting drug reduces risk of second ischemic stroke without bleeding concerns

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic (clot-caused) stroke without raising bleeding concerns, according to a preliminary late-breaking science presentation at the American Stroke Association's International Stroke Conference 2026.

6 Feb 2026

Antiplatelet medications linked to worse outcomes in people hospitalized with a brain bleed

Analysis of hospital registry data found that people who were hospitalized due to bleeding in the brain and who had taken multiple antiplatelet medications, or medications stronger than aspirin, were more likely to die before leaving the hospital compared to those not taking any antiplatelet medication, according to a preliminary study to be presented at the American Stroke Association's International Stroke Conference 2026.

29 Jan 2026

One-month dual therapy strategy offers advantages for AFib patients and clinicians

New research found a simplified clot-preventing medication regimen following stent placement in adults with atrial fibrillation was just as safe and effective in preventing strokes, heart attack and death, when compared to a standard year-long treatment regimen, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

No advantage found in modulating antiplatelet therapy intensity after complex stenting

There was no benefit to modulating the intensity of antiplatelet therapy compared with standard antiplatelet therapy in high-risk patients who had undergone complex stenting procedures, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

4 Sep 2025

Cardiovascular screening in men aged 60 to 64 years does not reduce all-cause mortality

An invitation to attend a comprehensive screening examination for the early signs of cardiovascular disease (CVD) did not reduce all-cause death among men aged 60 to 64 years, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

2 Sep 2025

P2Y12 inhibitors linked to lower rates of cardiovascular events compared to aspirin

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, with no increased risk of major bleeding, finds a study published by The BMJ today.

5 Jun 2025

Research shows clopidogrel as better long-term therapy than aspirin after PCI

People at high risk for recurrent cardiac events following percutaneous coronary intervention (PCI), a procedure to open blocked arteries, experienced significantly better outcomes with clopidogrel rather than aspirin as their long-term antiplatelet therapy, according to research presented at the American College of Cardiology's Annual Scientific Session.

31 Mar 2025

Research reveals optimal duration of dual antiplatelet therapy after stent implantation

Patients who have a stent implanted to open a blocked coronary artery face dual risks of developing blood clots and of having excessive bleeding in the months following the procedure.

29 Mar 2025

Intermittent fasting cuts heart attack risk by preventing dangerous blood clots

Intermittent fasting may reduce the risk of blood clots and cardiovascular disease by inhibiting platelet activation.

2 Mar 2025

Controversy surrounds landmark anti-platelet drug trial

An investigation published by The BMJ today raises new concerns over the landmark clinical trial (PLATO) that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in the US and Brilique in Europe), manufactured by AstraZeneca.

11 Dec 2024

Edoxaban monotherapy superior to dual therapy in patients with high-risk AF and stable CAD

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation (AF) and stable coronary artery disease (CAD), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Combined use of popular diabetes drugs likely to offer additional protection against heart and kidney disease

New research shows combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to offer additional protection against heart and kidney disease in patients with diabetes.

8 Jul 2024

Study shows reduced bleeding risk with ticagrelor monotherapy after percutaneous coronary intervention

People who have had a heart attack or who are at risk for a heart attack and who stopped taking aspirin alongside the P2Y12 inhibitor ticagrelor one month after undergoing percutaneous coronary intervention (PCI) saw a significantly reduced risk of clinically meaningful bleeding with no increased risk of clotting-related adverse events at 12 months compared with patients who continued taking aspirin and ticagrelor for a full year, in a study presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024